Trial: 201805157

A Randomized Phase II Study of Nivolumab After Combined Modality Therapy (CMT) in High Risk Anal Cancer

Phase

III

Principal Investigator

Aranha, Olivia

Disease Site

Anus

Learn more about this study at: clinicaltrials.gov